宏观视角（含综合性分析报告、投融资、管线等涉及多类别领域的报告）
请复制链接至电脑/手机浏览器查阅
序号 | 发布单位 | 标题 | 链接 | 日期 | 备注 |
1 | 艾昆纬 | Medication Treatments for Diabetes and Obesity in Canada, 2021-2025，An independent IQVIA report on drug utilization data.（加拿大糖尿病与肥胖的药物治疗，2021-2025年——一份关于药物使用数据的独立IQVIA报告） | https://www.iqvia.com/-/media/iqvia/pdfs/canada/publications/diabetes-and-obesity-2021-2025-report_en_final.pdf | 2026/10/14 | |
2 | 艾昆纬 | Prescription Opioid Usage Trends in Canada, 2021-2025，An independent IQVIA report on measuring and understanding the use of prescription opioids dispensed in Canada.（加拿大处方阿片类药物使用趋势，2021-2025年——一份关于加拿大处方阿片类药物使用情况的独立IQVIA报告） | https://www.iqvia.com/-/media/iqvia/pdfs/canada/publications/iqvia_opioids_report_2026_en_final.pdf | 2026/10/14 | |
3 | Morgan Stanley | Australia Consumer and Healthcare GLP-1s: A Repeat Prescription（澳大利亚消费者与医疗保健-GLP-1类药物:重复处方） | https://www.fxbaogao.com/view?id=5764143&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/10/13 | 需注册账号，每日限制次数阅读、收费下载 |
欣峰制药&E药经理人研究院 | 2026中国口溶膜产业发展白皮书：技术演进、市场格局与跨界融合新机遇 | https://www.fxbaogao.com/view?id=5757294&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/10/13 | 需注册账号，每日限制次数阅读、收费下载 | |
5 | B of A SECURITIES | US Biopharmaceuticals Catalysts through YE27: Big Pharma and SMID biopharma Top 10 event （美国生物制药：至2027年末的催化剂——大型制药及中小市值生物制药十大事件） | https://www.fxbaogao.com/view?id=5758073&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/10/12 | 需注册账号，每日限制次数阅读、收费下载 |
6 | 中邮证券 | 医药生物行业：厉兵秣马，拥抱顺风：从CRL、IQV、TMO看龙头CXO公司的AI观（及全球CXO2026中报业绩跟踪） | https://pdf.dfcfw.com/pdf/H3_AP202610091830246074_1.pdf?1791549950000.pdf | 2026/10/9 | |
7 | 艾昆纬 | Regulatory Data Protection in India（印度的监管数据保护） | https://www.iqvia.com/-/media/iqvia/pdfs/india/white-papers/regulatory-data-protection-in-india.pdf | 2026/10/9 | |
8 | 发现报告 | 2026RAS行业深度报告：概况、现状及代表公司全梳理 | https://www.fxbaogao.com/view?id=5738089&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/10/8 | 需注册账号，每日限制次数阅读、收费下载 |
9 | 艾昆纬 | Medication Treatments for Mental Health Disorders in Canada - An independent IQVIA report on medication use, 2021–2025（加拿大心理健康障碍的药物治疗，2021-2025年——一份关于药物使用数据的独立IQVIA报告） | https://www.iqvia.com/-/media/iqvia/pdfs/canada/publications/mental-health-report-2021-2025_en_final.pdf | 2026/10/8 | |
10 | McKinsey | Medtech needs more than a market rotation to win back investors （医疗技术需要的不仅仅是市场轮换来赢回投资者） | https://www.mckinsey.com/industries/life-sciences/our-insights/medtech-needs-more-than-a-market-rotation-to-win-back-investors#/ | 2026/10/6 | 需提供信息下载 |
11 | 艾昆纬 | Beyond AI Hype: Improving Patient Outcomes Through Smarter Regulatory Affairs（超越人工智能炒作：通过更智能的监管事务改善患者治疗效果） | https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/2026/beyond-ai-hype-improving-patient-outcomes-through-smarter-regulatory-affairs.pdf | 2026/10/2 | |
12 | 高盛 | Global Healthcare: Pharmaceuticals: Takeaways from our China biopharma trip （全球医疗：制药行业，中国生物医药调研要点） | https://www.fxbaogao.com/view?id=5735838&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/10/1 | 需注册账号，每日限制次数阅读、收费下载 |
13 | 国信证券 | 中外生物医药创新模式研究——基于中美欧日创新生态的比较分析 | https://www.fxbaogao.com/view?id=5734554&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/9/30 | 需注册账号，每日限制次数阅读、收费下载 |
14 | Capgemini | From manufacturing execution systems to intelligence-Powering AI-driven pharma operations （从制造执行系统到智能赋能人工智能驱动的制药运营） | https://www.capgemini.com/wp-content/uploads/2026/09/Pharma-MES-PoV.pdf | 2026/9/28 | |
15 | 毕马威 | 2025年患者项目调研报告 | https://app.jingsocial.com/mF/cms/pdfPreview/n4KNNDmJAKnhGaVgwD2eP7/none/n4KNNDmJAKnhGaVgwD2eP7/GH6R7DmP5hP5ck7rLMFejQ1 | 2026/9/28 | |
16 | 西南证券 | 创新药专题：中国之声闪耀2026WCLC | https://pdf.dfcfw.com/pdf/H3_AP202609241829865596_1.pdf?1790271626000.pdf | 2026/9/24 | |
17 | 开源证券 | 医药生物行业点评报告：创新药行业进入快速成长期，关注BD出海价值兑现机会 | https://pdf.dfcfw.com/pdf/H3_AP202609241829856701_1.pdf?1790258663000.pdf | 2026/9/24 | |
18 | 国金证券 | 医药健康行业研究：聚焦2026 WCLC大会：肺癌治疗迭代，中国新药崛起 | https://www.fxbaogao.com/view?id=5719877&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/9/22 | 需注册账号，每日限制次数阅读、收费下载 |
19 | 西南证券 | AI制药专题：全流程赋能制药未来，成药验证未来可期 | https://pdf.dfcfw.com/pdf/H3_AP202609221829759948_1.pdf?1790096802000.pdf | 2026/9/22 | |
20 | 毕马威 | 中亚生命科学行业市场概览 | https://assets.kpmg.com/content/dam/kpmgsites/cn/pdf/zh/2026/09/central-asia-life-sciences-industry-market-overview.pdf.coredownload.inline.pdf | 2026/9/21 | |
21 | OECD | Strengthening the EU’s Medical Supply Chains International Co-operation and New Technologies for Better Emergency Preparedness （加强欧盟的医疗供应链：国际合作和新技术，以更好地做好应急准备） | https://www.fxbaogao.com/view?id=5713925&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/9/21 | 需注册账号，每日限制次数阅读、收费下载 |
22 | McKinsey | AI drug discovery: Focusing on what matters most （人工智能药物发现：专注于最重要的事情） | https://www.mckinsey.com/industries/life-sciences/our-insights/ai-drug-discovery-focusing-on-what-matters-most | 2026/9/21 | |
23 | 国元国际 | 科技巨头投入加大，AI制药行业迎来快速增长期 | https://www.fxbaogao.com/view?id=5710383&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/9/18 | 需注册账号，每日限制次数阅读、收费下载 |
24 | 高盛 | Global Healthcare: Pharmaceuticals: China Biopharma: Continued momentum amidst emerging policy dynamics （全球医疗健康：中国生物制药持续增长与新兴政策动态） | https://www.fxbaogao.com/view?id=5711483&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/9/18 | 需注册账号，每日限制次数阅读、收费下载 |
25 | 西南证券 | 医药行业2026年半年报总结：医药上游板块表现较好，寻找业绩估值相对匹配个股 | https://pdf.dfcfw.com/pdf/H3_AP202609181829584191_1.pdf?1789718479000.pdf | 2026/9/18 | |
26 | 开源证券 | 医药生物行业深度报告：原料药板块业绩增速企稳回升，创新药及CDMO转型公司进入兑现期 | https://pdf.dfcfw.com/pdf/H3_AP202609171829517593_1.pdf?1789665839000.pdf | 2026/9/17 | |
27 | 头豹研究院 | 2026年中国AI制药行业深度研究：十年烧钱终见Ⅲ期，AI能否炼成下一款重磅新药？ | https://pdf.dfcfw.com/pdf/H3_AP202610091830271648_1.pdf?1791574962000.pdf | 2026/9/16 | |
28 | 上海交通大学 | 2025全球医工交叉科学前沿蓝皮书 | https://www.fxbaogao.com/view?id=5723807&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/9/16 | 需注册账号，每日限制次数阅读、收费下载 |
29 | 国信证券 | A股生物医药行业2026半年报总结：创新药及产业链持续高景气 | https://pdf.dfcfw.com/pdf/H3_AP202609151829425636_1.pdf?1789507623000.pdf | 2026/9/15 | |
30 | McKinsey | Backbones and networks: A blueprint for the biopharma plant of the future（骨干和网络：未来生物制药工厂的蓝图） | https://www.mckinsey.com/industries/life-sciences/our-insights/backbones-and-networks-a-blueprint-for-the-biopharma-plant-of-the-future#/ | 2026/9/15 | |
31 | Clarivate | Optimizing expedited regulatory pathways to speed time to market （优化加速监管路径，加快创新疗法上市速度） | https://www.fxbaogao.com/view?id=5702392&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/9/15 | 需注册账号，每日限制次数阅读、收费下载 |
32 | 诚通证券 | 医药行业2026上半年业绩总结：总体平稳，创新药产业链细分亮点突出 | https://www.fxbaogao.com/view?id=5700540&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/9/14 | 需注册账号，每日限制次数阅读、收费下载 |
33 | Deutsche Bank | 2026 AI Biopharma review: the dream is still Morphic, not yet mortal （2026年AI制药行业回顾：仍存期许，未达成熟） | https://www.fxbaogao.com/view?id=5704192&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/9/14 | 需注册账号，每日限制次数阅读、收费下载 |
34 | Deutsche Bank | Life Science Tools, Diagnostics & CROs（生命科学工具、诊断与CRO行业研究） | https://www.fxbaogao.com/view?id=5698161&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/9/14 | 需注册账号，每日限制次数阅读、收费下载 |
35 | Morgan Stanley | Biotechnology Moonshots: Where Low Expectations Meet Transformational Upside （生物科技“登月计划”：低预期与变革性上行空间交汇） | https://www.fxbaogao.com/view?id=5695117&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/9/11 | 需注册账号，每日限制次数阅读、收费下载 |
36 | 头豹研究院 | 2026年中国甲状腺功能紊乱治疗药物行业：福元医药双品种挑战默克，谁能主导迈向百亿的甲状腺用药市场 | https://pdf.dfcfw.com/pdf/H3_AP202609241829870734_1.pdf?1790279532000.pdf | 2026/9/11 | |
37 | 西南证券 | 港股医药行业2026年中报总结：港股创新药和CXO板块业绩趋势向好 | https://www.fxbaogao.com/view?id=5690309&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/9/9 | 需注册账号，每日限制次数阅读、收费下载 |
38 | 高盛 | 2Q/1H Wrap up: Re-entry thesis playing out; CDMOs lead while assessing next leg of healthcare re-rating（中国医疗健康脉搏2Q/1H回顾：再入局逻辑兑现CDMO领跑医疗健康再评级的下一阶段） | https://www.fxbaogao.com/view?id=5690521&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/9/9 | 需注册账号，每日限制次数阅读、收费下载 |
39 | 浙商证券 | 2026年上半年创新药业绩综述 国内商业化快速兑现，海外商业化有望爆发 | https://www.fxbaogao.com/view?id=5692228&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/9/10 | 需注册账号，每日限制次数阅读、收费下载 |
40 | 中银证券 | 医药行业26年中报综述：医药中报业绩逐步修复，行业进入反转周期 | https://pdf.dfcfw.com/pdf/H3_AP202609091829160476_1.pdf?1788946648000.pdf | 2026/9/9 | |
41 | 东北证券 | 2026年医药中报总结及下半年投资策略：创新药BD和商业化持续兑现，CXO超预期，传统板块筑底拐点 | https://www.fxbaogao.com/view?id=5685594&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/9/9 | 需注册账号，每日限制次数阅读、收费下载 |
42 | 浙商证券 | CXO&上游2026H1业绩综述&2026Q4投资策略：新需求，新业绩 | https://www.fxbaogao.com/view?id=5683924&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/9/8 | 需注册账号，每日限制次数阅读、收费下载 |
43 | 招商证券 | 创新药板块2026年中报总结 | https://www.fxbaogao.com/view?id=5681958&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/9/7 | 需注册账号，每日限制次数阅读、收费下载 |
44 | Morgan Stanley | Investor Presentation | Japan Pharmaceuticals （日本制药行业投资者报告会） | https://www.fxbaogao.com/view?id=5676645&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/9/4 | 需注册账号，每日限制次数阅读、收费下载 |
45 | 华安证券 | A+H医药2026年中报总结：出清、出海与盈利拐点 | https://www.fxbaogao.com/view?id=5672580&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/9/3 | 需注册账号，每日限制次数阅读、收费下载 |
46 | 中邮证券 | 医药生物深度报告：三重指标验证临床CRO景气度恢复，多因素共振下头部临床CRO将迎上行周期 | https://pdf.dfcfw.com/pdf/H3_AP202609031828954009_1.pdf?1788438644000.pdf | 2026/9/3 | |
47 | 国信证券 | 寻找未被满足的临床需求(6)——白癜风：从抑制炎症到清除免疫记忆 | https://pdf.dfcfw.com/pdf/H3_AP202609031828945691_1.pdf?1788426740000.pdf | 2026/9/2 | |
48 | 国金证券 | 制药板块26年中报业绩总结：赛道持续分化，创新药板块高增长 | https://pdf.dfcfw.com/pdf/H3_AP202609021828926016_1.pdf?1788366985000.pdf | 2026/9/2 | |
49 | 国家药监局 | 药品监督管理统计年度数据（2025年） | https://www.nmpa.gov.cn/zwgk/tjxx/tjnb/20260901171526163.html | 2026/9/1 | |
50 | 中邮证券 | 医药2026年中报总结：创新药产业链维持高景气 | https://pdf.dfcfw.com/pdf/H3_AP202609011828893167_1.pdf?1788333777000.pdf | 2026/9/1 | |
51 | 国金证券 | 制药供应链板块2026年中报业绩总结：景气度上行持续验证，内外需共振带动业绩加速 | https://pdf.dfcfw.com/pdf/H3_AP202609021828915848_1.pdf?1788358813000.pdf | 2026/9/1 | |
52 | 东吴证券 | 医药行业2026H1总结报告：CXO、创新药及科研服务板块引领业绩增长 | https://pdf.dfcfw.com/pdf/H3_AP202609011828838626_1.pdf?1788247593000.pdf | 2026/9/1 | |
53 | 中商产业研究院 | 2026年中国生物制造产业发展白皮书 | https://www.fxbaogao.com/view?id=5661647&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/8/31 | 需注册账号，每日限制次数阅读、收费下载 |
54 | 东方证券 | 实验猴短缺：周期波动，还是产业拐点？ | https://www.fxbaogao.com/view?id=5659753&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/8/31 | 需注册账号，每日限制次数阅读、收费下载 |
55 | 摩熵咨询 | 2026年眼科抗VEGF药物市场研究专题报告 | https://consult.pharnexcloud.com/report/detail/115987.html | 2026/8/28 | 需注册账号，每日限制次数下载 |
56 | 中邮证券 | AI4S（二）：制药临界点突破前夜：新范式逐渐成型，分子验证需求正崛起 | https://pdf.dfcfw.com/pdf/H3_AP202608271828554157_1.pdf?1787859559000.pdf | 2026/8/27 | |
57 | 东北证券 | 海外AI制药系列1：五大技术路径、市场测算与监管演进全景，AI重构制药工业核心变量 | https://www.fxbaogao.com/view?id=5645734&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/8/26 | 需注册账号，每日限制次数阅读、收费下载 |
58 | 浙商证券 | AI制药行业深度报告：新时代，新跃迁 | https://www.fxbaogao.com/view?id=5641961&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/8/26 | 需注册账号，每日限制次数阅读、收费下载 |
59 | BERNSTEIN | US Biopharma: AI in Drug Discovery - separating the hype from the real goals & progress（美国生物制药：药物发现中的AI——去伪存真） | https://www.fxbaogao.com/view?id=5644703&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/8/26 | 需注册账号，每日限制次数阅读、收费下载 |
60 | 国投证券 | 创新药行业报告：出海之势长风破浪，景气上行踏浪而来 | https://www.fxbaogao.com/view?id=5639983&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/8/26 | 需注册账号，每日限制次数阅读、收费下载 |
61 | 国信证券 | 国内外生物医药发展现状、趋势演进与市场空间 | https://www.fxbaogao.com/view?id=5639973&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/8/26 | 需注册账号，每日限制次数阅读、收费下载 |
62 | 浙商证券 | 创新药资产美元化系列报告：创新药：新市场，新估值 | https://www.fxbaogao.com/view?id=5635992&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/8/25 | 需注册账号，每日限制次数阅读、收费下载 |
63 | Morgan Stanley | Biopharma | North America Clinical Trial Pipeline Track （北美生物制药：临床试验管线跟踪） | https://www.fxbaogao.com/view?id=5624427&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/8/20 | 需注册账号，每日限制次数阅读、收费下载 |
64 | 招商证券 | AI制药专题行业：从算法叙事到管线价值，临床兑现与商业化爆发在即 | https://www.fxbaogao.com/view?id=5615774&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/8/19 | 需注册账号，每日限制次数阅读、收费下载 |
65 | 东方财富证券 | 自身免疫药物专题：从慢病大单品到精准免疫，国产创新药进入差异化兑现期 | https://www.fxbaogao.com/view?id=5615774&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/8/19 | 需注册账号，每日限制次数阅读、收费下载 |
66 | 招银国际 | 海外CXO/生命科学上游2Q26业绩剖析：早研需求已达实质性向上拐点，普遍上调2026年业绩指引 | https://pdf.dfcfw.com/pdf/H3_AP202608191828131353_1.pdf?1787132730000.pdf | 2026/8/19 | |
67 | 高盛 | GLOBAL HEALTHCARE The Obesity Evolution: Framing the generic semaglutide opportunity in Canada and Brazil （全球医疗行业：仿制司美格鲁肽在加拿大和巴西的机遇） | https://www.fxbaogao.com/view?id=5612700&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/8/17 | 需注册账号，每日限制次数阅读、收费下载 |
68 | 丁香园 | 2026攻坚银发海啸-阿尔茨海默病创新药研发格局及趋势洞察报告 | https://pdf.dfcfw.com/pdf/H3_AP202608301828730403_1.pdf?1788100468000.pdf | 2026/8/14 | |
69 | 国信证券 | 消费医疗：行业现状、海外经验与重点赛道分析：寻找消费医疗板块被低估的优质标的 | https://pdf.dfcfw.com/pdf/H3_AP202608141827961363_1.pdf?1786696369000.pdf | 2026/8/13 | |
70 | 艾昆纬 | Accelerating Drug Development: Insights from 2020–2024 Rapid Approvals （加速药物开发：2020–2024年快速审批洞察） | https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/2026/accelerated-drug-development-white-paper-for-ddrs.pdf | 2026/8/13 | |
71 | 国泰海通证券 | 2026年医药产业政策上半年回顾&下半年展望：政策再细化，产业再优化 | https://www.fxbaogao.com/view?id=5593917&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/8/11 | 需注册账号，每日限制次数阅读、收费下载 |
72 | 招商证券 | MASH行业深度报告：市场广阔而药物有限，多项重磅管线将迎来关键节点 | https://www.fxbaogao.com/view?id=5593353&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/8/10 | 需注册账号，每日限制次数阅读、收费下载 |
73 | 东方证券 | 医药行业专题报告：AI重构创新药研发底座 | https://www.fxbaogao.com/view?id=5592760&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/8/10 | 需注册账号，每日限制次数阅读、收费下载 |
74 | 东吴证券 | 创新药估值方法论——从分子到公司 | https://pdf.dfcfw.com/pdf/H3_AP202608081827775706_1.pdf?1786187506000.pdf | 2026/8/8 | |
75 | 海通国际 | AI制药系列一：从模型跃迁到验证闭环 | https://www.fxbaogao.com/view?id=5587590&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/8/7 | 需注册账号，每日限制次数阅读、收费下载 |
76 | 沙利文 | 2026年港股18A生物科技行业发展蓝皮书 | https://www.fxbaogao.com/view?id=5582225&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/8/4 | 需注册账号，每日限制次数阅读、收费下载 |
77 | Morgan Stanley | Biopharma | North America A picture is worth a thousand words（一图胜千言-北美生物制药企业分析报告） | https://www.fxbaogao.com/view?id=5577905&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/8/3 | 需注册账号，每日限制次数阅读、收费下载 |
78 | 华创证券 | 全球生物药CDMO供给紧平衡，平台型Biotech具重估潜力——韩国生物医药调研反馈 | https://www.fxbaogao.com/view?id=5575819&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/8/2 | 需注册账号，每日限制次数阅读、收费下载 |
79 | 上海证券 | 医药生物行业ESG专题报告（一）：厚植绿色底色，医药发展新引擎 | https://pdf.dfcfw.com/pdf/H3_AP202608011827561332_1.pdf?1785664341000.pdf | 2026/7/31 | |
80 | 艾昆纬 | If better Weight-Loss Drugs keep improving, Consumer Health will be reshaped | https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/2026/if-better-weight-loss-drugs-keep-improving_-consumer-health-will-be-reshaped---iqvia-consumer-health.pdf | 2026/7/31 | |
81 | 摩熵咨询 | 2026年HIV流行病学趋势及热门靶点药物市场表现洞察 | https://consult.pharnexcloud.com/report/detail/115975.html | 2026/7/31 | 需注册账号，每日限制次数下载 |
82 | 摩熵咨询 | 2026年多发性骨髓瘤流行病学趋势及热门靶点药物市场表现洞察 | https://consult.pharnexcloud.com/report/detail/115974.html | 2026/7/31 | 需注册账号，每日限制次数下载 |
83 | 摩熵咨询 | 2026年非小细胞肺癌流行病学趋势及热门靶点药物市场表现洞察 | https://consult.pharnexcloud.com/report/detail/115973.html | 2026/7/31 | 需注册账号，每日限制次数下载 |
84 | 发现报告 | 2026创新药行业深度报告：概况、现状及代表公司全梳理 | https://www.fxbaogao.com/view?id=5562313&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/7/28 | 需注册账号，每日限制次数阅读、收费下载 |
85 | 国金证券 | 产业、业绩与资金三维共振，把握创新药底部布局机遇 | https://www.fxbaogao.com/view?id=5566489&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/7/28 | 需注册账号，每日限制次数阅读、收费下载 |
86 | Biomedtracker | 2026 Biomedtracker Datamonitor Healthcare Post-EHA Report | https://www.fxbaogao.com/view?id=5562708&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/7/27 | 需注册账号，每日限制次数阅读、收费下载 |
87 | 国信证券 | 寻找未被满足的临床需求（5）：RAS抑制剂有望改写胰腺癌治疗指南 | https://www.fxbaogao.com/view?id=5561362&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/7/27 | 需注册账号，每日限制次数阅读、收费下载 |
88 | HSBC | China Healthcare: AI in Drug Discovery（AIDD） | https://www.fxbaogao.com/view?id=5559494&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/7/24 | 需注册账号，每日限制次数阅读、收费下载 |
89 | 国金证券 | 医药产业研究深度：谁将是创新药中2025年的三星、美光和SK海力士 | https://pdf.dfcfw.com/pdf/H3_AP202607271827385884_1.pdf?1785174202000.pdf | 2026/7/24 | |
90 | Morgan Stanley | Biopharma | North America A picture is worth a thousand words | https://www.fxbaogao.com/view?id=5560150&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/7/24 | 需注册账号，每日限制次数阅读、收费下载 |
91 | 安永 | 从中国创新到全球价值：中国创新药全球合作与交易观察 | https://pdf.dfcfw.com/pdf/H3_AP202607231827273287_1.pdf?1784791155000.pdf | 2026/7/23 | |
92 | BERNSTEIN | China CDMO: Primer on Peptide CDMOs Part 1 - Supply-side | https://www.fxbaogao.com/view?id=5553238&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/7/23 | 需注册账号，每日限制次数阅读、收费下载 |
93 | 西部证券 | 那些未充分满足的临床需求系列报告之一：地图样萎缩(GA)的市场研究 | https://www.fxbaogao.com/view?id=5553243&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/7/23 | 需注册账号，每日限制次数阅读、收费下载 |
94 | 天风证券 | 2015-2025中国创新药投资十年复盘 | https://www.fxbaogao.com/view?id=5654566&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/7/22 | 需注册账号，每日限制次数阅读、收费下载 |
95 | Evaluate | 2026世界前瞻：重磅药物。更宏大的问题。 | https://pdf.dfcfw.com/pdf/H3_AP202607221827239603_1.pdf?1784706709000.pdf | 2026/7/22 | |
96 | 安永 | 从中国创新到全球价值：中国创新药全球合作与交易观察 | https://www.fxbaogao.com/view?id=5549102&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/7/22 | 需注册账号，每日限制次数阅读、收费下载 |
97 | Citi | China Healthcare 1H26 Results Preview: BD Deals to alleviate Pharma sales; CDMOs solid | https://www.fxbaogao.com/view?id=5551880&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/7/21 | 需注册账号，每日限制次数阅读、收费下载 |
98 | Morgan Stanley | China Pharmaceuticals 1H26 Earnings Preview: BD Outlook Outshining Transient Domestic Disruption | https://www.fxbaogao.com/view?id=5553155&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/7/21 | 需注册账号，每日限制次数阅读、收费下载 |
99 | 摩熵咨询 | FDA新药审评图谱-CDER批准趋势与中国创新药出海启示 | https://pdf.dfcfw.com/pdf/H3_AP202607231827273292_1.pdf?1784791708000.pdf | 2026/7/21 | |
100 | 国信证券 | CXO行业系列专题报告（5）：新分子蓬勃发展，多肽、ADC、寡核苷酸CRDMO大放异彩 | https://pdf.dfcfw.com/pdf/H3_AP202607211827207664_1.pdf?1784649530000.pdf | 2026/7/21 | |
101 | Evaluate | 2026全球医药市场展望 | https://www.fxbaogao.com/view?id=5545898&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/7/20 | 需注册账号，每日限制次数阅读、收费下载 |
102 | 国盛证券 | 医药生物2026年中期投资策略：反弹趋势确立，看好创新药产业链及医药科技 | https://www.fxbaogao.com/view?id=5543806&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/7/20 | 需注册账号，每日限制次数阅读、收费下载 |
103 | ITIF | Commercializing Canadian Health Research: The Case for Targeting Grants and Increasing Overall Investment | https://www.fxbaogao.com/view?id=5546285&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/7/20 | 需注册账号，每日限制次数阅读、收费下载 |
104 | 波士顿咨询 | 印度制药与生命科学创新机遇：规模化构建，转向科学 | https://pdf.dfcfw.com/pdf/H3_AP202607191827100543_1.pdf?1784457201000.pdf | 2026/7/19 | |
105 | 毕马威 | 中国医药行业数字化生态发展报告 | https://assets.kpmg.com/content/dam/kpmgsites/cn/pdf/zh/2026/07/the-digital-ecology-development-report-of-china-s-pharmaceutical-industry.pdf.coredownload.inline.pdf | 2026/7/17 | |
106 | 西南证券 | 医药行业2026年中期投资策略：医药K型分化，关注科技主题、出海、红利 | https://pdf.dfcfw.com/pdf/H3_AP202607161827032480_1.pdf?1784238528000.pdf | 2026/7/16 | |
107 | 国联民生证券 | 医药行业2026年中期投资策略：五大判断，创新、升级、出海、供应链、跨界 | https://www.fxbaogao.com/view?id=5538163&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/7/16 | 需注册账号，每日限制次数阅读、收费下载 |
108 | 东北证券 | 创新研发与业绩兑现，重点关注创新药板块 | https://www.fxbaogao.com/view?id=5539893&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/7/15 | 需注册账号，每日限制次数阅读、收费下载 |
109 | 招商证券 | 汇添富创新药相关产业链ETF投资价值分析 | https://www.fxbaogao.com/view?id=5535874&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/7/14 | 需注册账号，每日限制次数阅读、收费下载 |
110 | BERNSTEIN | China Pharma & Biotech: 2Q/1H26 earnings preview - amid anti-corruption and VBP, innovative leaders separate from the pack | https://www.fxbaogao.com/view?id=5532448&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/7/14 | 需注册账号，每日限制次数阅读、收费下载 |
111 | 高盛 | Americas Life Sciences Tools & Diagnostics: 2Q26 Earnings Preview: GS Tools Tracker and China Stimulus Tracker Update | https://www.fxbaogao.com/view?id=5532525&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/7/14 | 需注册账号，每日限制次数阅读、收费下载 |
112 | 高盛 | GLOBAL HEALTHCARE The Cardiology Renaissance: Lp(a): Mid-year data to read through to a new cardiovascular drug class | https://www.fxbaogao.com/view?id=5532515&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/7/14 | 需注册账号，每日限制次数阅读、收费下载 |
113 | BERNSTEIN | India Healthcare: World without humans? A growing infertility crisis, an aging world, Biopharma's growth engine | https://www.fxbaogao.com/view?id=5530007&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/7/13 | 需注册账号，每日限制次数阅读、收费下载 |
114 | 万联证券 | 2026年中期医药生物行业投资策略报告：估值筑底，创新破局 | https://pdf.dfcfw.com/pdf/H3_AP202607131826927396_1.pdf?1783960227000.pdf | 2026/7/13 | |
115 | 国金证券 | 医药健康行业研究：产业、业绩与资金三维共振，把握创新药底部布局机遇 | https://pdf.dfcfw.com/pdf/H3_AP202607141826943209_1.pdf?1784016467000.pdf | 2026/7/11 | |
116 | 头豹研究院 | 2026年口腔癌药物市场格局深度分析：国产免疫药占比63%形成三强鼎立，神州细胞/百泰生物借医保弯道超车 | https://pdf.dfcfw.com/pdf/H3_AP202607271827390474_1.pdf?1785182265000.pdf | 2026/7/10 | |
117 | Morgan Stanley | Biopharma | North America A picture is worth a thousand words | https://www.fxbaogao.com/view?id=5526783&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/7/10 | 需注册账号，每日限制次数阅读、收费下载 |
118 | 浦银国际证券 | 医药行业2026年中期展望：全球化延续，兑现决定分化 | https://pdf.dfcfw.com/pdf/H3_AP202607141826955598_1.pdf?1784044753000.pdf | 2026/7/10 | |
119 | 浦银国际证券 | 中国创新药：出海重塑价值，兑现决定分化-恢复覆盖九家公司，首选科伦博泰、百济神州、复宏汉霖 | https://pdf.dfcfw.com/pdf/H3_AP202607141826955543_1.pdf?1784044438000.pdf | 2026/7/10 | |
120 | J.P.Morgan | Pharmaceutical Sector Data Book - Clinical Trial Data – Obesity Drugs | https://www.fxbaogao.com/view?id=5521988&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/7/9 | 需注册账号，每日限制次数阅读、收费下载 |
121 | 医药魔方 | 国家基本药物目录2026版变化规律与政策导向深度解读 | https://bydrug.pharmcube.com/report/detail/13c784e5eeee40ed96f1156c2b9e1991 | 2026/7/9 | 需注册账号，每日限制次数下载 |
122 | 东海证券 | 医药生物行业2026年中期投资策略：行业底部夯实，风物长宜放远 | https://pdf.dfcfw.com/pdf/H3_AP202607091826851603_1.pdf?1783632592000.pdf | 2026/7/9 | |
123 | 中国医学创新联盟 | 中国医院创新转化报告：2026 | https://pdf.dfcfw.com/pdf/H3_AP202607091826833064_1.pdf?1783591083000.pdf | 2026/7/7 | |
124 | 艾昆纬 | The Landscape for Obesity Medications in Australia | https://www.iqvia.com/-/media/iqvia/pdfs/australia-and-new-zealand/white-papers/the-landscape-for-obesity-medications-in-australia.pdf | 2026/7/7 | |
125 | 国泰海通证券 | MASH药物行业研究报告：掘金百亿级代谢慢病赛道，关注纤维化改善终点 | https://www.fxbaogao.com/view?id=5511984&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/7/6 | 需注册账号，每日限制次数阅读、收费下载 |
126 | 东吴证券 | 创新药疾病透视系列行业研究第七期：OSA治疗中创新药的竞争格局分析 | https://pdf.dfcfw.com/pdf/H3_AP202607051826726109_1.pdf?1783247218000.pdf | 2026/7/5 | |
127 | 上海证券 | 医药生物行业2026年中期投资策略：蓄力寻先机，创新越山海 | https://pdf.dfcfw.com/pdf/H3_AP202607021826651395_1.pdf?1782986884000.pdf | 2026/7/1 | |
128 | J.P.Morgan | Medical Technologies & Services Sector China and Japan market conditions are bottoming out; US tariff rebates are a tailwind; beware the risks from a sharp surge in AI-related investment | https://www.fxbaogao.com/view?id=5505752&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/7/1 | 需注册账号，每日限制次数阅读、收费下载 |
129 | 摩熵咨询 | 创新药CRO与医疗器械CRO商业模式差异分析 | https://pdf.dfcfw.com/pdf/H3_AP202607041826721791_1.pdf?1783248150000.pdf | 2026/7/1 | |
130 | 远东资信 | 区域生物医药“十五五规划”与行业发展分析：华东篇 | https://pdf.dfcfw.com/pdf/H3_AP202607011826639809_1.pdf?1782980941000.pdf | 2026/6/30 | |
131 | 思宇MedTech&眼未来 | 2026全球眼科创新与增长白皮书 | https://pdf.dfcfw.com/pdf/H3_AP202607031826682263_1.pdf?1783071257000.pdf | 2026/6/30 | |
132 | McKinsey | Biopharma R&D: The evolving formula for discovery and development | https://www.mckinsey.com/mgi/our-research/biopharma-r-and-d-the-evolving-formula-for-discovery-and-development | 2026/6/30 | 需提供信息下载 |
133 | McKinsey | From linear gates to learning loops: Rewiring biopharma R&D with AI | https://www.mckinsey.com/industries/life-sciences/our-insights/from-linear-gates-to-learning-loops-rewiring-biopharma-r-and-d-with-ai#/ | 2026/6/29 | 需提供信息下载 |
134 | ITIF | 中国生物制药竞争力日益增强，需要美国的回应 | https://pdf.dfcfw.com/pdf/H3_AP202607011826626709_1.pdf?1782919028000.pdf | 2026/6/29 | |
135 | 铜娃娃罕见病关爱中心&罕见星球 | 肝豆状核变性（WD）患者生存状况调研报告2026 | https://www.fxbaogao.com/view?id=5498891&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/6/29 | 需注册账号，每日限制次数阅读、收费下载 |
136 | 摩熵咨询 | AI制药产业化观察：从工具增效走向价值兑现 | https://consult.pharnexcloud.com/report/detail/115832.html | 2026/6/26 | 需注册账号，每日限制次数下载 |
137 | 中原证券 | 医药行业2026年半年度策略：风掠江心乱月影，雨涤苍穹焕新阳 | https://www.fxbaogao.com/view?id=5496804&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/6/26 | 需注册账号，每日限制次数阅读、收费下载 |
138 | 医麦客&IBI EXPO | 破茧2026-类器官与器官芯片行业研究白皮书 | https://www.fxbaogao.com/view?id=5495768&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/6/25 | 需注册账号，每日限制次数阅读、收费下载 |
139 | 国家药监局 药品审评中心 | 中国新药注册临床试验进展年度报告（2025年） | https://www.cde.org.cn/main/news/viewInfoCommon/3c3e3f37c4b56cdd4896ef6256f5efcb | 2026/6/22 | |
140 | 浙商证券 | 医药生物行业2026年半年度投资策略：“新”生 | https://www.fxbaogao.com/view?id=5491501&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/6/22 | 需注册账号，每日限制次数阅读、收费下载 |
141 | 东方证券 | CXO景气度跟踪专题：景气高位运行，业绩稳步兑现 | https://www.fxbaogao.com/view?id=5486158&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/6/20 | 需注册账号，每日限制次数阅读、收费下载 |
142 | 东吴证券 | 十大未来产业系列之四——生物制造 | https://www.fxbaogao.com/view?id=5486012&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/6/19 | 需注册账号，每日限制次数阅读、收费下载 |
143 | Morgan Stanley | Investor Presentation | Japan Pharmaceuticals | https://www.fxbaogao.com/view?id=5487095&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/6/18 | 需注册账号，每日限制次数阅读、收费下载 |
144 | BERNSTEIN | China Pharma & Biotech: Policy headwinds and implications for valuation | https://www.fxbaogao.com/view?id=5484968&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/6/18 | 需注册账号，每日限制次数阅读、收费下载 |
145 | 华西证券 | 自免药物行业深度研究报告：从大分子时代迈向精准与口服新阶段 | https://www.fxbaogao.com/view?id=5485382&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/6/16 | 需注册账号，每日限制次数阅读、收费下载 |
146 | 摩熵咨询 | 儿童药时代：政策破局下的创新药蓝海与立项机会洞察 | https://consult.pharnexcloud.com/report/detail/115760.html | 2026/6/15 | 需注册账号，每日限制次数下载 |
147 | 摩熵咨询 | 新药医保落地背景下中国痛风及高尿酸血症诊疗格局与市场趋势洞察报告 | https://consult.pharnexcloud.com/report/detail/115762.html | 2026/6/15 | 需注册账号，每日限制次数下载 |
148 | 中邮证券 | 2026SID大会总结：自免行业报告（三）：后Dupi时代，行业的下一个期待是什么？ | https://pdf.dfcfw.com/pdf/H3_AP202606151823569128_1.pdf?1781539610000.pdf | 2026/6/15 | |
149 | Morgan Stanley | Finger On The Pulse US SMID Cap Biotech Beat Edition 65: More M&A, back on track for a record year | https://www.fxbaogao.com/view?id=5480525&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/6/14 | 需注册账号，每日限制次数阅读、收费下载 |
150 | Morgan Stanley | Can Innovation Ease Alzheimer's Growing Burden? Leaning in on Brain Shuttles | https://www.fxbaogao.com/view?id=5478253&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/6/11 | 需注册账号，每日限制次数阅读、收费下载 |
151 | 东莞证券 | 医药生物行业2026年中期投资策略：聚焦创新兑现 把握医药下半年结构性机遇 | https://pdf.dfcfw.com/pdf/H3_AP202606111823455435_1.pdf?1781196325000.pdf | 2026/6/11 | |
152 | 头豹研究院 | 2026年中国冠心病治疗药物市场洞察报告：创新研发驱动临床价值升级，创新转型与仿创协同发展趋势 | https://pdf.dfcfw.com/pdf/H3_AP202607091826850039_1.pdf?1783626051000.pdf | 2026/6/10 | |
153 | 摩熵咨询 | 靶免联合时代下的中国肝癌药物竞争格局与机会洞察 | https://pdf.dfcfw.com/pdf/H3_AP202606101823432441_1.pdf?1781124574000.pdf | 2026/6/8 | |
154 | 医麦客 | 破茧2026·mRNA与小核酸药物行业研究白皮书 | https://www.fxbaogao.com/view?id=5468624&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid=#page=1 | 2026/6/8 | 需注册账号，每日限制次数阅读、收费下载 |
155 | Morgan Stanley | The Ozempic cliff: generic risks, opportunities and bottlenecks | https://www.fxbaogao.com/view?id=5468339&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/6/7 | 需注册账号，每日限制次数阅读、收费下载 |
156 | 中国医药企业管理协会 | 医药工业发展形势及“十五五”展望 | https://pdf.dfcfw.com/pdf/H3_AP202606061823323264_1.pdf?1780751316000.pdf | 2026/6/6 | |
157 | 国金证券 | 医药健康行业研究：引领迭代浪潮，国产创新药迈向全球舞台中央 | https://pdf.dfcfw.com/pdf/H3_AP202606081823361565_1.pdf?1780940204000.pdf | 2026/6/5 | |
158 | Morgan Stanley | Biopharma | North America A picture is worth a thousand words | https://www.fxbaogao.com/view?id=5466150&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/6/5 | 需注册账号，每日限制次数阅读、收费下载 |
159 | 摩熵咨询 | 2025年中国药品销售市场分析报告 | https://consult.pharnexcloud.com/report/detail/115702.html | 2026/6/5 | 需注册账号，每日限制次数下载 |
160 | 头豹研究院 | 2026年中国口腔医疗服务市场发展洞察报告：Z世代崛起，如何重新定义“微笑经济”？ | https://pdf.dfcfw.com/pdf/H3_AP202606161823609747_1.pdf?1781639326000.pdf | 2026/6/3 | |
161 | 西南证券 | 创新药专题：中国之声闪耀2026ASCO | https://pdf.dfcfw.com/pdf/H3_AP202606021823164658_1.pdf?1780427544000.pdf | 2026/6/2 | |
162 | 摩熵咨询 | 胃癌药物研发与市场趋势报告 | https://consult.pharnexcloud.com/report/detail/115683.html | 2026/6/1 | 需注册账号，每日限制次数下载 |
163 | 东吴证券 | 制药行业：中国创新药为什么具有全球竞争力？ | https://pdf.dfcfw.com/pdf/H3_AP202605311823104339_1.pdf?1780254404000.pdf | 2026/5/31 | |
164 | 太平洋证券 | 小核酸行业系列报告（二）：肝脏之外——Beyond the Liver:Knockin’on Extrahepatic Delivery’s Door | https://pdf.dfcfw.com/pdf/H3_AP202606011823120449_1.pdf?1780323945000.pdf | 2026/5/29 | |
165 | 国金证券 | 下一代颠覆性创新疗法系列1：靶蛋白降解迎来商业化元年 | https://pdf.dfcfw.com/pdf/H3_AP202605311823105587_1.pdf?1780239985000.pdf | 2026/5/29 | |
166 | 美国癌症协会 | 2026癌症事实与数据 | https://www.fxbaogao.com/view?id=5443444&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/5/29 | 需注册账号，每日限制次数阅读、收费下载 |
167 | Morgan Stanley | China Biotechnology Innovation Dawn 2.0: From Wholesale to Bespoke | https://www.fxbaogao.com/view?id=5455942&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/5/28 | 需注册账号，每日限制次数阅读、收费下载 |
168 | 医药魔方 | 中国创新药出海交易“新玩法”：趋势、挑战与全球化交易格局 | https://bydrug.pharmcube.com/report/detail/6904511a4c8649d3954100f1f74dc170 | 2026/5/28 | 需注册账号，每日限制次数下载 |
169 | 国信证券 | 医药生物2026ASCO年会摘要总结：关注国产双抗、ADC等创新分子 | https://pdf.dfcfw.com/pdf/H3_AP202605281822933925_1.pdf?1779956047000.pdf | 2026/5/27 | |
170 | 国泰海通证券 | 代谢领域系列报告：降脂药物研发：BIC研发导向，中国工程师红利优势领域 | https://www.fxbaogao.com/view?id=5439848&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/5/27 | 需注册账号，每日限制次数阅读、收费下载 |
171 | 医药魔方 | 重塑全球价值：中国创新药出海制胜策略与实践 | https://bydrug.pharmcube.com/report/detail/d64ab102a79f48b0b527957709fdde41 | 2026/5/25 | 需注册账号，每日限制次数下载 |
172 | 华源证券 | 医药行业：2025年&2026Q1总结-创新药及产业链表现亮眼，内需资产整体承压 | https://pdf.dfcfw.com/pdf/H3_AP202605221822692521_1.pdf?1779479955000.pdf | 2026/5/22 | |
173 | 摩熵咨询 | 乳腺癌药物竞争格局与创新趋势研究报告 | https://consult.pharnexcloud.com/report/detail/115619.html | 2026/5/22 | 需注册账号，每日限制次数下载 |
174 | 摩熵咨询 | 降血脂药物市场洞察报告 | https://consult.pharnexcloud.com/report/detail/115620.html | 2026/5/22 | 需注册账号，每日限制次数下载 |
175 | BERNSTEIN | US SMlD-Cap Biopharmaceuticals US Biotech: initiating an investment relationship with Biotech? it's complicated... | https://www.fxbaogao.com/view?id=5434451&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/5/21 | 需注册账号，每日限制次数阅读、收费下载 |
176 | 开源证券 | 医药行业2026年中期投资策略：创新引领，多点开花 | https://pdf.dfcfw.com/pdf/H3_AP202605211822647898_1.pdf?1779385149000.pdf | 2026/5/19 | |
177 | 招银国际 | 中国医药：AI有望改变创新药研发范式 | https://www.fxbaogao.com/view?id=5426274&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/5/19 | 需注册账号，每日限制次数阅读、收费下载 |
178 | 诚通证券 | 医药行业2025年及26Q1业绩总结：总体平稳，创新药产业链一枝独秀 | https://pdf.dfcfw.com/pdf/H3_AP202605191822449834_1.pdf?1779215947000.pdf | 2026/5/18 | |
179 | Capgemini | Orchestrating the agentic revolution across life sciences | https://www.capgemini.com/wp-content/uploads/2026/05/PoV_Agentic-AI-in-LS_May-2026.pdf | 2026/5/18 | |
180 | PitchBook | 新兴技术研究：生物医药风险投资趋势 | https://pdf.dfcfw.com/pdf/H3_AP202605171822382659_1.pdf?1779029444000.pdf | 2026/5/17 | |
181 | 开源证券 | 医药生物行业深度报告：技术进步驱动合成生物学行业快速发展 | https://pdf.dfcfw.com/pdf/H3_AP202605151822348368_1.pdf?1778865526000.pdf | 2026/5/15 | |
182 | 国信证券 | A股生物医药行业2025年报&2026一季报总结：创新药及产业链持续高景气 | https://pdf.dfcfw.com/pdf/H3_AP202605151822349409_1.pdf?1778867195000.pdf | 2026/5/15 | |
183 | 西南证券 | 医药行业2025年报及2026年一季报总结：CXO、创新药业绩保持较好增长 | https://pdf.dfcfw.com/pdf/H3_AP202605151822356556_1.pdf?1778880967000.pdf | 2026/5/15 | |
184 | 国家药监局药品审评中心 | 2025年度药品审评报告 | https://www.cde.org.cn/main/news/viewInfoCommon/b93aba16ec47467317057dca4aac8437 | 2026/5/13 | |
185 | Brand Finance | Healthcare 2026 The annual report on the most valuable and strongest pharma, medical devicesand healthcare services brands | https://www.fxbaogao.com/view?id=5413436&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/5/12 | 需注册账号，每日限制次数阅读、收费下载 |
186 | 国金证券 | 医药配套行业行业研究：CXO行业深度报告：内外需共振向上，新分子赋能行业持续扩容 | https://pdf.dfcfw.com/pdf/H3_AP202605141822300058_1.pdf?1778745470000.pdf | 2026/5/11 | |
187 | 上海证券 | 医药生物行业两会“十五五”专题报告：医改纵深推进，创新智慧引领 | https://pdf.dfcfw.com/pdf/H3_AP202605121822211821_1.pdf?1778601342000.pdf | 2026/5/11 | |
188 | 东莞证券 | 医药生物行业2025年及2026年一季度业绩综述：Q1板块业绩好转，关注细分景气方向 | https://pdf.dfcfw.com/pdf/H3_AP202605111822153075_1.pdf?1778511406000.pdf | 2026/5/11 | |
189 | 东吴证券 | 医药行业2025年度及2026Q1总结报告：创新药、CXO及科研服务高增长，受益于BD出海及国内回暖 | https://pdf.dfcfw.com/pdf/H3_AP202605091822102943_1.pdf?1778332051000.pdf | 2026/5/9 | |
190 | 摩熵咨询 | 2026年乳腺癌流行病学趋势及热门靶点药物市场表现洞察 | https://pdf.dfcfw.com/pdf/H3_AP202605121822189882_1.pdf?1778573055000.pdf | 2026/5/8 | |
191 | Capgemini | Life sciences engineering and R&D pulse 2026 | https://www.capgemini.com/wp-content/uploads/2026/05/lifesciences-erandd-pulse2026.pdf | 2026/5/7 | |
192 | 中邮证券 | 医药2025年报及2026一季报总结：创新药及产业链维持高景气 | https://pdf.dfcfw.com/pdf/H3_AP202605071822027216_1.pdf?1778168990000.pdf | 2026/5/7 | |
193 | 艾昆纬 | eCTD 4.0: Implementation Including Understanding of Regional Differences and Benefits | https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/2026/ectd-40-implementation-including-understanding-of-regional-differences-and-benefits.pdf | 2026/5/6 | |
194 | 国泰海通证券 | 大药诞生之自免系列二：技术迭代领跑自免3.0时代，2026密集催化迎产业变革 | https://www.fxbaogao.com/view?id=5403270&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/5/6 | 需注册账号，每日限制次数阅读、收费下载 |
195 | 中银证券 | 医药行业25年年报及26年一季报综述 | https://pdf.dfcfw.com/pdf/H3_AP202605061821983997_1.pdf?1778077070000.pdf | 2026/5/6 | |
196 | 国金证券 | 医药行业制药板块25年&26Q1业绩总结：赛道分化，创新药板块高速增长 | https://pdf.dfcfw.com/pdf/H3_AP202605051821973834_1.pdf?1778055077000.pdf | 2026/5/6 | |
197 | McKinsey | Targeted and timely: Curating aesthetic care for GLP-1 patients | https://www.mckinsey.com/industries/life-sciences/our-insights/targeted-and-timely-curating-aesthetic-care-for-glp-1-patients | 2026/5/1 | 需提供信息下载 |
198 | 国金证券 | 医药健康行业研究：终端需求逐步复苏，看好全年景气度反转 | https://pdf.dfcfw.com/pdf/H3_AP202605051821967957_1.pdf?1777993833000.pdf | 2026/5/1 | |
199 | 摩熵咨询 | 2026年HPV赛道深度研究报告：流行病学、竞争格局与人群画像 | https://consult.pharnexcloud.com/report/detail/115618.html | 2026/4/30 | 需注册账号，每日限制次数下载 |
200 | 欧洲疾病预防控制中心 | 百日咳2024年年度流行病学报告 | https://pdf.dfcfw.com/pdf/H3_AP202604301821820215_1.pdf?1777561156000.pdf | 2026/4/30 | |
201 | 毕马威 | 2026年中国生命科学行业概览及未来展望 | https://assets.kpmg.com/content/dam/kpmgsites/cn/pdf/zh/2026/04/china-life-sciences-sector-overview-and-outlook-2026.pdf.coredownload.inline.pdf | 2026/4/29 | |
202 | 中国电子信息产业发展研究院电子信息研究所 | 人工智能赋能生物制造研究 | https://pdf.dfcfw.com/pdf/H3_AP202604281821651609_1.pdf?1777366272000.pdf | 2026/4/28 | |
203 | 摩熵咨询 | 2026年肝癌流行病学趋势及热门靶点药物市场表现洞察 | https://pdf.dfcfw.com/pdf/H3_AP202605121822189872_1.pdf?1778571658000.pdf | 2026/4/28 | |
204 | 东方证券 | 医药生物行业动态跟踪：2026 ASCO国内公司重点研究前瞻-ASCO盛会将至，中国创新药强势突围 | https://www.fxbaogao.com/view?id=5387108&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/4/28 | 需注册账号，每日限制次数阅读、收费下载 |
205 | 国家药品不良反应监测中心 | 国家药品不良反应监测年度报告 （2025年） | https://www.cdr-adr.org.cn/center_news/202604/t20260427_51496.html | 2026/4/27 | |
206 | 国信证券 | 医药行业快评ASCO年会标题发布，多个国产创新药研究成果入选口头报告 | https://www.fxbaogao.com/view?id=5378942&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/4/26 | 需注册账号，每日限制次数阅读、收费下载 |
207 | 摩熵咨询 | 2025年中国临床试验数据洞察 | https://consult.pharnexcloud.com/report/detail/115171.html | 2026/4/22 | 需注册账号，每日限制次数下载 |
208 | 中国医药创新促进会 | PMRE in Asia Volume 1: Regulatory Environment Identification and Clarification of the Differences in Regulatory Environment between Asian Economies | https://hqiv.oss-cn-beijing.aliyuncs.com/static/s/ych/download/2026年亚洲医药市场与监管环境报告1：监管报告.pdf | 2026/4/21 | |
209 | 中国医药创新促进会 | PMRE in Asia Volume 2: Information on the Market Environments of Asian Economies | https://hqiv.oss-cn-beijing.aliyuncs.com/static/s/ych/download/2026年亚洲医药市场与监管环境报告2：市场报告.pdf | 2026/4/21 | |
210 | UBS AG | China Healthcare Marketing book - Biotech and CRO | https://www.fxbaogao.com/view?id=5369405&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/4/21 | 需注册账号，每日限制次数阅读、收费下载 |
211 | Capgemini | The resurgence of manufacturing: Reindustrialization of Europe and the US – 2026 | https://www.capgemini.com/wp-content/uploads/2026/04/2000426CRI_Reindustrialization-_Interactive-1-1.pdf | 2026/4/20 | |
212 | UBS AG | China Healthcare AACR 2026: Highlights from our biopharma coverage | https://www.fxbaogao.com/view?id=5366414&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/4/20 | 需注册账号，每日限制次数阅读、收费下载 |
213 | 国信证券 | 创新药盘点系列报告（26）：四大支柱后，HFrEF心衰领域还有哪些升级空间？ | https://pdf.dfcfw.com/pdf/H3_AP202604201821331457_1.pdf?1776697198000.pdf | 2026/4/20 | |
214 | 安永(中国)企业咨询 | 医药行业穿越盈利的迷雾：安永“本土药企盈利引擎”模型1.0——供应链与财务篇 | https://pdf.dfcfw.com/pdf/H3_AP202604171821280037_1.pdf?1776411232000.pdf | 2026/4/17 | |
215 | 中国食品药品检定研究院 | 国家药品抽检年报（2025） | https://www.nifdc.org.cn//nifdc/bshff/gjchj/gjchjtzgg/202604161331002003989.html | 2026/4/16 | |
216 | 上海证券 | 医药生物行业2026年春季投资策略：“跟随”到“引领”，花开终有时 | https://pdf.dfcfw.com/pdf/H3_AP202604171821285929_1.pdf?1776424025000.pdf | 2026/4/16 | |
217 | 欧洲制药工业协会联合会 | 医疗投资与成果：在中央和东欧 | https://pdf.dfcfw.com/pdf/H3_AP202604151821247436_1.pdf?1776325786000.pdf | 2026/4/16 | |
218 | 国泰海通证券 | 自免行业报告系列：从MNC重磅BD看自免赛道技术迭代：大药诞生之自免系列一：千亿自免赛道迎代际更迭，MNC加速抢滩下一代管线 | https://www.fxbaogao.com/view?id=5357289&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/4/16 | 需注册账号，每日限制次数阅读、收费下载 |
219 | 高盛 | GLOBAL HEALTHCARE: BIOTECHNOLOGY | https://www.fxbaogao.com/view?id=5358247&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/4/16 | 需注册账号，每日限制次数阅读、收费下载 |
220 | 德勤 | 借力中国创新生态，重塑全球竞争力——外资生物医药企业在中国的战略重构与增长路径 | https://www.deloitte.com/content/dam/assets-zone1/cn/zh/docs/industries/life-sciences-health-care/2026/deloitte-accessing-biopharma-innovation-in-china-zh-260409.pdf | 2026/4/15 | |
221 | UBS AG | Women's Health Innovation | https://www.fxbaogao.com/view?id=5355520&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/4/14 | 需注册账号，每日限制次数阅读、收费下载 |
222 | McKinsey | Shaping the future of Japan’s pharmaceutical operations | https://www.mckinsey.com/industries/life-sciences/our-insights/shaping-the-future-of-japans-pharmaceutical-operations | 2026/4/14 | 需提供信息下载 |
223 | BERNSTEIN | US Pharma and Biotech: MGA in 2026 is running hot... Our top picks through year end | https://www.fxbaogao.com/view?id=5351234&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/4/13 | 需注册账号，每日限制次数阅读、收费下载 |
224 | OECD | The Health and Economic Benefits of Tackling Non-Communicable Diseases | https://www.fxbaogao.com/view?id=5346054&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/4/11 | 需注册账号，每日限制次数阅读、收费下载 |
225 | 高盛 | US Pharma-Charts We Are Watching | https://www.fxbaogao.com/view?id=5344564&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/4/9 | 需注册账号，每日限制次数阅读、收费下载 |
226 | 国信证券 | 海内外CXO行业2025年总结：投融资复苏，景气度向好 | https://pdf.dfcfw.com/pdf/H3_AP202604081821058818_1.pdf?1775653848000.pdf | 2026/4/8 | |
227 | Norstella | 2026年医药研发年度报告 | https://www.fxbaogao.com/view?id=5346130&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/4/7 | 需注册账号，每日限制次数阅读、收费下载 |
228 | 东方证券 | 减重专题报告：MNC管线完善，重点转向开发平台 | https://www.fxbaogao.com/view?id=5336348&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/4/5 | 需注册账号，每日限制次数阅读、收费下载 |
229 | OECD | Addressing the Costs and Care for Long COVID：THE LONG SHADOW OF THE PANDEMIC | https://www.fxbaogao.com/view?id=5335242&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/4/4 | 需注册账号，每日限制次数阅读、收费下载 |
230 | 禾开生物 | A+B (AI+BD)双重冲击下的自免新药研发新策略 | https://www.fxbaogao.com/view?id=5350432&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/4/3 | 需注册账号，每日限制次数阅读、收费下载 |
231 | 中国抗癌协会宫颈癌专业委员会 | 2025中国宫颈癌诊疗现状白皮书 | https://pdf.dfcfw.com/pdf/H3_AP202604031821004171_1.pdf?1775209886000.pdf | 2026/4/3 | |
232 | 毕马威 | 释放潜力：生成式人工智能对中国生命科学行业的影响 | https://assets.kpmg.com/content/dam/kpmgsites/cn/pdf/zh/2026/03/the-impact-of-generative-artificial-intelligence-on-the-life-sciences-industry-in-china.pdf.coredownload.inline.pdf | 2026/3/31 | |
233 | 头豹研究院 | 2026年中国牙周病治疗行业洞察报告：高发病率叠加低就诊率，牙周疾病年轻化如何解决？ | https://pdf.dfcfw.com/pdf/H3_AP202604141821195172_1.pdf?1776195951000.pdf | 2026/3/31 | |
234 | 上海科创银行 | 中国医疗健康行业资本市场趋势 | https://pdf.dfcfw.com/pdf/H3_AP202604101821108129_1.pdf?1775812969000.pdf | 2026/3/31 | |
235 | 艾昆纬 | Southeast Asia and Pakistan Overview: The Emerging Hub for Clinical Trial Scale Up | https://www.iqvia.com/-/media/iqvia/pdfs/asia-pacific/insight-brief/sea-and-pakistan-insight-brief.pdf | 2026/3/27 | |
236 | 广发证券 | 英矽智能(03696.HK)独特AI制药平台，加速创新药研发 | https://www.fxbaogao.com/view?id=5324638&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/3/26 | 需注册账号，每日限制次数阅读、收费下载 |
237 | 国金证券 | 医药健康行业研究：医疗产业链提价专题-原料药及耗材迎来提价契机，行业景气度有望回升 | https://pdf.dfcfw.com/pdf/H3_AP202603241820712595_1.pdf | 2026/3/23 | |
238 | 头豹研究院 | 2026年中国早泄治疗用药行业概览：当“快”不再是赞美，如何满足男性健康市场沉默的刚需？ | https://pdf.dfcfw.com/pdf/H3_AP202604011820958141_1.pdf?1775072672000.pdf | 2026/3/20 | |
239 | Parexel | New Medicines, Novel Insights: Accelerating the New Frontiers in Neuroscience An Executive Summary | https://www.fxbaogao.com/view?id=5309843&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/3/20 | 需注册账号，每日限制次数阅读、收费下载 |
240 | 山西证券 | 医药行业2026年投资策略：多层次支付体系持续完善，中国创新初现锋芒 | https://pdf.dfcfw.com/pdf/H3_AP202603191820642544_1.pdf?1773930438000.pdf | 2026/3/19 | |
241 | 欧洲疾病预防控制中心 | 莱姆病年度流行病学报告（2023年） | https://pdf.dfcfw.com/pdf/H3_AP202603191820651332_1.pdf?1773951242000.pdf | 2026/3/19 | |
242 | 华泰证券 | https://www.fxbaogao.com/view?id=5307722&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/3/18 | 需注册账号，每日限制次数阅读、收费下载 | |
243 | ITIF | Lessons From Europe’s Loss of Biopharma Leadership, and Its Attempts to Recov | https://www.fxbaogao.com/view?id=5307944&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/3/18 | 需注册账号，每日限制次数阅读、收费下载 |
244 | 中国银河证券 | 医药生物行业“十五五”规划纲要解读报告：以人为本，医疗健康系统性升级 | https://www.fxbaogao.com/view?id=5308823&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/3/15 | 需注册账号，每日限制次数阅读、收费下载 |
245 | WHO | Arenaviridae Research & Development Roadmap | https://cdn.who.int/media/docs/default-source/consultation-rdb/arenaviridae-r-d-roadmap.pdf?sfvrsn=f898cc59_3&download=true | 2026/3/12 | |
246 | 国泰海通证券 | 2026年医药产业政策展望：“两会”绘蓝图，“十五五”新征途 | https://www.fxbaogao.com/view?id=5298223&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/3/12 | 需注册账号，每日限制次数阅读、收费下载 |
247 | 国信证券 | 创新药盘点系列报告（25）：IgA肾病药物已进入商业化兑现期 | https://pdf.dfcfw.com/pdf/H3_AP202603121820524391_1.pdf?1773341960000.pdf | 2026/3/12 | |
248 | 东吴证券 | 创新药进入收获期，仿制药CRO/CDMO困境反转 | https://consult.pharnexcloud.com/report/detail/114791.html | 2026/3/12 | 需注册账号，每日限制次数下载 |
249 | 艾昆纬 | 推动精准肿瘤学发展：美国肿瘤标志物检测趋势 | https://pdf.dfcfw.com/pdf/H3_AP202603191820636906_1.pdf?1773912340000.pdf | 2026/3/9 | |
250 | 药智 | 2025年度中国医药领域专利发展分析报告 | https://db.yaozh.com/reportcenter/info/id/550.html | 2026/3/9 | 需提供信息查阅、下载 |
251 | 国泰海通证券 | AI制药持续进展，跨国药企布局加速 | https://www.fxbaogao.com/view?id=5291802&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/3/9 | 需注册账号，每日限制次数阅读、收费下载 |
252 | 万联证券 | 医药生物行业深度报告：投融资与出海双轮驱动，CXO迎来景气度修复与全球化新周期 | https://pdf.dfcfw.com/pdf/H3_AP202603091820422805_1.pdf?1773095033000.pdf | 2026/3/9 | |
253 | 信达证券 | 新兴生物技术专题报告：小核酸药物方兴未艾，海外创新与国内崛起共振 | https://pdf.dfcfw.com/pdf/H3_AP202603091820404498_1.pdf?1773055030000.pdf | 2026/3/9 | |
254 | 信达证券 | 临床CRO行业深度跟踪：供需关系改善，有望驱动订单量价齐升 | https://pdf.dfcfw.com/pdf/H3_AP202603091820404498_1.pdf?1773055030000.pdf | 2026/3/9 | |
255 | 国金证券 | 医药行业研究：靶蛋白降解：下一代颠覆性治疗范式迎来商业化元年 | https://pdf.dfcfw.com/pdf/H3_AP202603101820434538_1.pdf?1773128891000.pdf | 2026/3/6 | |
256 | 国泰海通证券 | 延续心血管优势，核酸药物递送加速破局 | https://www.fxbaogao.com/view?id=5286735&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/3/5 | 需注册账号，每日限制次数阅读、收费下载 |
257 | 头豹研究院 | 2026年过敏性鼻炎药物品牌推荐双效合一，快速通鼻 | https://pdf.dfcfw.com/pdf/H3_AP202603051820308917_1.pdf?1772741320000.pdf | 2026/3/5 | |
258 | 药智 | 2025年度重点医药政策盘点 | https://db.yaozh.com/reportcenter/info/id/544.html | 2026/3/5 | 需提供信息查阅、下载 |
259 | 埃森哲 | 从实验室到生产线 重新定义生物制药 | https://pdf.dfcfw.com/pdf/H3_AP202602281820143602_1.pdf?1772313511000.pdf | 2026/2/28 | |
260 | 病痛挑战公益基金会&沙利文 | 2026中国罕见病行业趋势观察报告 | https://www.fxbaogao.com/view?id=5283648&requestId=&query={"reportTypes":["12","13"]}&index=0&pid=&xid= | 2026/2/27 | 需注册账号，每日限制次数阅读、收费下载 |
261 | 浙商证券 | 临床前CRO系列专题报告（一）：实验猴供需缺口大，持续看好临床前CRO深度研究 | https://www.fxbaogao.com/view?id=5278312&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/2/27 | 需注册账号，每日限制次数阅读、收费下载 |
262 | 毕马威 | 2025年毕马威全球生命科学行业首席执行官展望 | https://assets.kpmg.com/content/dam/kpmgsites/cn/pdf/zh/2026/01/life-sciences.pdf.coredownload.inline.pdf | 2026/2/27 | |
263 | 国信证券 | 海外制药企业2025Q4&全年业绩回顾：2026会是下一个BD大年吗？ | https://pdf.dfcfw.com/pdf/H3_AP202602271820085454_1.pdf?1772184151000.pdf | 2026/2/26 | |
264 | 国泰海通证券 | FXI/FXIa抑制剂行业研究报告：从靶点到管线，FXI引领抗凝产业新变革 | https://www.fxbaogao.com/view?id=5273273&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/2/25 | 需注册账号，每日限制次数阅读、收费下载 |
265 | 高盛 | Byte-ology: Quantifying AI’s value creation in drug development | https://www.fxbaogao.com/view?id=5272705&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/2/20 | 需注册账号，每日限制次数阅读、收费下载 |
266 | 上海现代服务业联合会&荣续智库 | 医养康行业ESG白皮书 | https://www.fxbaogao.com/view?id=5274571&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/2/20 | 需注册账号，每日限制次数阅读、收费下载 |
267 | Morgan Stanley | 北美生物制药行业观点更新 | https://www.fxbaogao.com/view?id=5272710&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/2/20 | 需注册账号，每日限制次数阅读、收费下载 |
268 | 新世纪评级 | 医药制造与流通行业2025年信用回顾与2026年展望 | https://www.fxbaogao.com/view?id=5274583&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/2/15 | 需注册账号，每日限制次数阅读、收费下载 |
269 | 药研社、CCHRPP | 2025年度全国注册类药物临床试验开展情况蓝皮书（上篇） | https://www.fxbaogao.com/view?id=5281581&requestId=2604133979136247&query=%7B%22keywords%22%3A%222025年度全国注册类药物临床试验开展情况蓝皮书%22%2C%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/2/13 | 需注册账号，每日限制次数阅读、收费下载 |
270 | McKinsey | Life sciences: Dealmaking gains momentum as strategic pressures intensify | https://www.mckinsey.com/capabilities/m-and-a/our-insights/life-sciences-dealmaking-gains-momentum-as-strategic-pressures-intensify | 2026/2/13 | 需提供信息下载 |
271 | DRAKE STAR PARTNERS | 远程医疗：2025年回顾与2026展望 | https://pdf.dfcfw.com/pdf/H3_AP202602101819861840_1.pdf?1770801724000.pdf | 2026/2/11 | |
272 | 中诚信国际 | 中国医药制造行业展望 | https://pdf.dfcfw.com/pdf/H3_AP202602111819874195_1.pdf?1770818751000.pdf | 2026/2/11 | |
273 | 德勤 | 2026年生命科学行业展望：生命科学行业高管认为企业财务前景比较乐观，但需在复杂国际局势中增强韧性 | https://pdf.dfcfw.com/pdf/H3_AP202602091819838338_1.pdf?1770663694000.pdf | 2026/2/9 | |
274 | 艾昆纬 | 优化早期临床试验以实现快速、基 于证据的决策 | https://pdf.dfcfw.com/pdf/H3_AP202602111819871322_1.pdf?1770809000000.pdf | 2026/2/9 | |
275 | ITIF | Tracking R&D Leadership: US Advantage Narrowing as China Gains Groun | https://www.fxbaogao.com/view?id=5263576&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/2/9 | 需注册账号，每日限制次数阅读、收费下载 |
276 | 艾昆纬 | 中东非洲药品商业洞察（第三十八版） | https://pdf.dfcfw.com/pdf/H3_AP202602281820143624_1.pdf?1772313733000.pdf | 2026/2/9 | |
277 | 美国癌症协会 | 医药：癌症事实与数据2026 | https://pdf.dfcfw.com/pdf/H3_AP202602071819822659_1.pdf?1770565915000.pdf | 2026/2/8 | |
278 | 药智 | 2025年度全球医药交易分析报告 | https://db.yaozh.com/reportcenter/info/id/537.html | 2026/2/6 | 需提供信息查阅、下载 |
279 | 广州中康资讯 | 《中国创新药蓝皮书（2025）》报告第一章 | https://pdf.dfcfw.com/pdf/H3_AP202602061819815133_1.pdf?1770416780000.pdf | 2026/2/6 | |
280 | 海通国际 | 美国医药调研反馈：肿瘤、代谢、自免、中枢神经系统赛道推荐更新 | https://www.fxbaogao.com/view?id=5259033&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/2/6 | 需注册账号，每日限制次数阅读、收费下载 |
281 | 西南证券 | 创新药专题：中国声音响彻2026年JPM大会 | https://pdf.dfcfw.com/pdf/H3_AP202602061819806370_1.pdf?1770389935000.pdf | 2026/2/6 | |
282 | 国泰海通证券 | 美国医药调研及JPM大会后反馈 | https://www.fxbaogao.com/view?id=5257867&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/2/5 | 需注册账号，每日限制次数阅读、收费下载 |
283 | 头豹研究院 | 2025年中国生物创新药市场跟踪报告：司美格鲁肽2025年第一季度市场回顾 | https://pdf.dfcfw.com/pdf/H3_AP202602041819774404_1.pdf?1770239567000.pdf | 2026/2/4 | |
284 | 智药局 | 2025 AI制药行业研究报告 | https://mp.weixin.qq.com/s/vqYQG9S2OJ-PtbaoRAa58A | 2026/2/4 | 需提供信息获取 |
285 | 药智 | 2025年度全球新药研发进展 | https://db.yaozh.com/reportcenter/info/id/535.html | 2026/2/2 | 需提供信息查阅、下载 |
286 | 信达证券 | “政策引导&技术支持”助力AI医疗崛起，蚂蚁阿福或成C端应用范例 | https://pdf.dfcfw.com/pdf/H3_AP202601301818576386_1.pdf?1769780721000.pdf | 2026/1/28 | |
287 | 摩熵咨询 | 2025全球罕见病行业发展报告：政策演进、市场趋势与领先企业布局 | https://pdf.dfcfw.com/pdf/H3_AP202601281818514005_1.pdf?1769635872000.pdf | 2026/1/26 | |
288 | 中邮证券 | 医药生物行业：国家统计局公布各项经济与人口数据，65岁及以上人口占比进一步提升 | https://pdf.dfcfw.com/pdf/H3_AP202601261818423652_1.pdf?1769439930000.pdf | 2026/1/26 | |
289 | 国信证券 | 医药生物行业2026年投资策略：关注创新出海，重视新技术方向 | https://pdf.dfcfw.com/pdf/H3_AP202601271818448366_1.pdf?1769501702000.pdf | 2026/1/26 | |
290 | 开源证券 | 北交所策略专题报告：药械出海获顶层设计加速，掘金北交所、新三板专精特新稀缺资产 | https://www.fxbaogao.com/view?id=5239334&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/1/25 | 需注册账号，每日限制次数阅读、收费下载 |
291 | PitchBook | The Chinese Biopharma Landscape: Where New Assets Are Born（新兴技术研究：中国生物医药格局：新资产诞生之地） | https://pdf.dfcfw.com/pdf/H3_AP202602071819822655_1.pdf?1770566304000.pdf | 2026/1/23 | |
292 | FDA | Advancing Health Through Innovation: New Drug Therapy Approvals 2025 | https://www.fda.gov/media/190705/download?attachment | 2026/1/23 | |
293 | 广州洞犀企业咨询 | 口腔产业投融资观察（2025） | https://pdf.dfcfw.com/pdf/H3_AP202601231818320268_1.pdf?1769185770000.pdf | 2026/1/23 | |
294 | 信达证券 | CXO行业跟踪报告：高景气度有望持续，JPM大会更新要点解读 | https://pdf.dfcfw.com/pdf/H3_AP202601231818303539_1.pdf?1769156127000.pdf | 2026/1/22 | |
295 | 摩熵咨询 | IgA肾病药物研发全景及已上市药物市场竞争格局报告 | https://consult.pharnexcloud.com/report/detail/114355.html | 2026/1/22 | 需注册账号，每日限制次数下载 |
296 | 中邮证券 | AI制药：从降本增效到分子创新，数据生产构筑长期壁垒 | https://pdf.dfcfw.com/pdf/H3_AP202601221818269607_1.pdf?1769094912000.pdf | 2026/1/22 | |
297 | 西南证券 | 药品专题报告：2025年药品BD出海总结 | https://pdf.dfcfw.com/pdf/H3_AP202601211818190934_1.pdf?1768988442000.pdf | 2026/1/21 | |
298 | WHO | WHO's response to the global mpox outbreak | https://cdn.who.int/media/docs/default-source/documents/health-topics/monkeypox/who-s-response-to-the-global-mpox-outbreak-donor-report-august-2025-september-2025.pdf?sfvrsn=e0c3fb48_3&download=true | 2026/1/21 | |
299 | 艾昆纬 | An Agentic AI-Powered Consumer Health Revolution: Scenarios on How Foundation Models and AI Agents Could Transform Discovery, Trust, and Commerce | https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/an-agentic-ai-powered-consumer-health-revolution.pdf | 2026/1/20 | |
300 | Vi Labs | State of AI in Wellness 2026 | https://www.fxbaogao.com/view?id=5232069&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/1/20 | 需注册账号，每日限制次数阅读、收费下载 |
301 | UBS AG | Q-Series Redux: Global Medtech Dragons through the gate; entering a new era ofcompetition | https://www.fxbaogao.com/view?id=5227146&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/1/15 | 需注册账号，每日限制次数阅读、收费下载 |
302 | 西南证券 | CXO跟踪报告：关注新分子的成长性与国内景气度修复的传导 | https://pdf.dfcfw.com/pdf/H3_AP202601151817082480_1.pdf?1768510551000.pdf | 2026/1/15 | |
303 | 硕远咨询 | 2025年中国母婴医疗服务行业市场研究报告 | https://www.fxbaogao.com/view?id=5223219&requestId=2601194187293593&query=%7B%22keywords%22%3A%222025年中国母婴医疗服务行业市场研究报告%22%2C%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/1/14 | 需注册账号，每日限制次数阅读、收费下载 |
304 | 药智 | 2025年度中国上市药品分析报告 | https://db.yaozh.com/reportcenter/info/id/528.html | 2026/1/14 | 需提供信息查阅、下载 |
305 | McKinsey | Capturing value from customer-centric medtech services | https://www.mckinsey.com/industries/life-sciences/our-insights/capturing-value-from-customer-centric-medtech-services | 2026/1/14 | 需提供信息下载 |
306 | 艾昆纬 | Clinical Trials in Tuberculosis Across Asia Pacific: Navigating Challenges and Exploring Solutions | https://www.fxbaogao.com/view?id=5241337&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/1/13 | 需注册账号，每日限制次数阅读、收费下载 |
307 | 药智 | 2025年度CDE药审分析报告 | https://db.yaozh.com/reportcenter/info/id/526.html | 2026/1/13 | 需提供信息查阅、下载 |
308 | Capgemini | Smart bet,only option,or both? Biopharma R&Dturns to Al. | https://www.capgemini.com/wp-content/uploads/2026/01/140126CRI_Gen-AI-in-Lifesciences-_Final-interactive-1.pdf | 2026/1/13 | |
309 | 头豹研究院 | 2025年中国带状疱疹疫苗行业洞察报告：免疫需求扩容+政策红利加持背景下，百克生物率先获批，国产疫苗如何承接市场？ | https://pdf.dfcfw.com/pdf/H3_AP202602241819998923_1.pdf?1771961794000.pdf | 2026/1/13 | |
310 | 艾昆纬 | A New, AI-Augmented Horizon for Safety and Pharmacovigilance:Expert Predictions for 2026 | https://www.fxbaogao.com/view?id=5224741&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/1/12 | 需注册账号，每日限制次数阅读、收费下载 |
311 | 艾昆纬 | 肺动脉高压临床试验教育者的演进与影响 | https://pdf.dfcfw.com/pdf/H3_AP202601071816825683_1.pdf | 2026/1/8 | |
312 | 万联证券 | 2025FDA新药全景：创新疗法与市场变革——医药生物行业跟踪报告 | https://pdf.dfcfw.com/pdf/H3_AP202601081816835695_1.pdf?1767860577000.pdf | 2026/1/8 | |
313 | 艾昆纬 | Trustworthy AI/ML for Patient Analytics and Research | https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/trustworthy-aiml-for-patient-analytics-and-research---final.pdf | 2026/1/7 | |
314 | 联合资信评估 | 医药制造行业2026年度信用风险展望 | https://pdf.dfcfw.com/pdf/H3_AP202601071816798126_1.pdf?1767808943000.pdf | 2026/1/7 | |
315 | McKinsey | The emerging epicenter: Asia’s role in biopharma’s future | https://www.mckinsey.com/industries/life-sciences/our-insights/the-emerging-epicenter-asias-role-in-biopharmas-future#/ | 2026/1/7 | 需提供信息下载 |
316 | 太平洋证券 | 医药行业2026年度策略报告：创新药产业链景气度持续提升 | https://pdf.dfcfw.com/pdf/H3_AP202601061815853167_1.pdf?1767687989000.pdf | 2026/1/6 | |
317 | 爱建证券 | 2026年医药行业投资策略：创新出海新征程，寻找需求新增量 | https://pdf.dfcfw.com/pdf/H3_AP202601061815857250_1.pdf?1767688824000.pdf | 2026/1/6 | |
318 | 招商证券 | 全球医药、医疗行业：2026年关注慢病迭代经营质量和现金流 | https://www.fxbaogao.com/view?id=5215406&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/1/5 | 需注册账号，每日限制次数阅读、收费下载 |
319 | 北京蛋黄科技 | 2025创新药及供应链年度创新白皮书：分化加速，行业回归平台与产品价值 | https://pdf.dfcfw.com/pdf/H3_AP202601041814560749_1.pdf?1767525627000.pdf | 2026/1/4 | |
320 | 太平洋证券 | 2026年度医药行业投资策略：聚焦创新，共赴新程 | https://pdf.dfcfw.com/pdf/H3_AP202601041814519850_1.pdf?1767519175000.pdf | 2026/1/4 | |
321 | 艾昆纬 | 中风领域的发展：关键管道和临床试验见解 | https://pdf.dfcfw.com/pdf/H3_AP202601041814560829_1.pdf?1767526172000.pdf | 2026/1/4 |
